CLL8: a randomised, phase III study to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CLL) who have responded to previous therapy

Trial Profile

CLL8: a randomised, phase III study to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CLL) who have responded to previous therapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Biomarker; Therapeutic Use
  • Acronyms CLARET
  • Most Recent Events

    • 26 Jun 2017 Status changed from completed to discontinued.
    • 11 Feb 2015 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 11 Aug 2012 Actual initiation date (12 Jun 2012) added as reported by EudraCT record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top